News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,001 Results
Type
Article (2420)
Company Profile (39)
Press Release (35542)
Section
Business (14153)
Career Advice (77)
Deals (2084)
Drug Delivery (8)
Drug Development (4094)
Employer Resources (10)
FDA (433)
Job Trends (761)
News (20172)
Policy (1051)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3467)
ALS (4)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (14)
Approvals (435)
Artificial intelligence (8)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (10)
Biotechnology (29)
Bladder cancer (5)
Brain cancer (5)
Breast cancer (16)
Cancer (110)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (39)
Cervical cancer (2)
Clinical research (3153)
Collaboration (83)
Compensation (41)
COVID-19 (180)
CRISPR (7)
C-suite (22)
Cystic fibrosis (2)
Data (89)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (461)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (9)
Earnings (4225)
Editorial (2)
Employer branding (1)
Employer resources (8)
Events (5985)
Executive appointments (80)
FDA (471)
Featured Employer (3)
Funding (70)
Gene editing (14)
Gene therapy (13)
GLP-1 (59)
Government (149)
Healthcare (705)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (11)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (992)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (17)
MASH (3)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1147)
Metabolic disorders (29)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (85)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (308)
Now hiring (4)
Obesity (14)
Opinion (15)
Ovarian cancer (9)
Pain (7)
Pancreatic cancer (2)
Parkinson's disease (4)
Partnered (1)
Patents (17)
Patient recruitment (2)
Peanut (1)
People (5613)
Pharmaceutical (5)
Phase I (1359)
Phase II (1582)
Phase III (842)
Pipeline (48)
Podcasts (4)
Policy (10)
Postmarket research (30)
Preclinical (584)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (19)
Real estate (420)
Recruiting (5)
Regulatory (792)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (21)
Series B (4)
Service/supplier (2)
Sickle cell disease (1)
Southern California (308)
Special edition (1)
Sponsored (1)
Startups (487)
Stomach cancer (1)
Supply chain (3)
The Weekly (1)
United States (1501)
Vaccines (25)
Venture capitalists (6)
Webinars (2)
Weight loss (9)
Women's health (1)
Worklife (1)
Date
Today (3)
Last 7 days (52)
Last 30 days (225)
Last 365 days (2575)
2025 (451)
2024 (2627)
2023 (2886)
2022 (3783)
2021 (4076)
2020 (3473)
2019 (2061)
2018 (1554)
2017 (1796)
2016 (1625)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1850)
Australia (297)
California (708)
Canada (123)
China (33)
Colorado (28)
Connecticut (10)
Delaware (3)
Europe (3792)
Florida (41)
Georgia (4)
Idaho (3)
Illinois (14)
India (1)
Indiana (28)
Japan (7)
Kansas (12)
Maryland (23)
Massachusetts (256)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (1)
New Jersey (57)
New York (42)
North Carolina (82)
Northern California (308)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (34)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (308)
Tennessee (2)
Texas (61)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (41)
Wisconsin (5)
38,001 Results for "aytu bioscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
February 12, 2025
·
17 min read
Press Releases
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
February 5, 2025
·
2 min read
Press Releases
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025
·
3 min read
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.
June 18, 2024
·
6 min read
Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024.
May 8, 2024
·
1 min read
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
April 3, 2024
·
1 min read
Press Releases
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 14, 2024
·
19 min read
Press Releases
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
October 15, 2024
·
1 min read
BioMidwest
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Aytu BioPharma, Inc. announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 23, 2024
·
1 min read
Business
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
February 14, 2024
·
14 min read
1 of 3,801
Next
